Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 10/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16596476 | 0.86 | ERN1 (0.48) | ERN1KCNH2PDK2LTA4H | |
| SCHEMBL1726249 | 0.80 | KCNH2 (0.55) | ERN1KCNH2PDK2LTA4H | |
| SCHEMBL20169301 | 0.79 | ERN1 (0.51) | ERN1NOTUMKCNH2PDK2LTA4H | |
| SCHEMBL28222643 | 0.79 | ERN1 (0.51) | ERN1KCNH2PDK2LTA4H | |
| SCHEMBL11551200 | 0.79 | COMT (0.41) | ERN1NOTUMKCNH2CASP3CYP1A2 | |
| SCHEMBL2698021 | 0.79 | NOTUM (0.61) | NOTUMCASP3IDO1CYP1A2 | |
| SCHEMBL14082898 | 0.78 | CSF1R (0.57) | — | |
| SCHEMBL20169308 | 0.76 | ERN1 (0.48) | ERN1KCNH2PDK2LTA4H | |
| SCHEMBL18304653 | 0.75 | KCNH2 (0.50) | ERN1KCNH2PDK2LTA4H | |
| SCHEMBL1323041 | 0.75 | KCNH2 (0.70) | ERN1KCNH2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3048107-B1 | BENZOBIS (THIADIAZOLE) DERIVATIVE, INK CONTAINING SAME, AND ORGANIC ELECTRONIC DEVICE USING SAME | FUTURE INK CORP (JP) | 2021-01-13 | — | — | EP | disclosed |
| EP-3386990-A1 | THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOF | Cadent Therapeutics, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9978954-B2 | Benzobis (thiadiazole) derivative, ink comprising same, and organic electronic device comprising same | UBE INDUSTRIES, LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9978954-B2 | Benzobis (thiadiazole) derivative, ink comprising same, and organic electronic device comprising same | UBE INDUSTRIES, LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| WO-2017100593-A1 | THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOF | LUC THERAPEUTICS (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017100599-A1 | THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOF | LUC THERAPEUTICS (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20160276598-A1 | BENZOBIS (THIADIAZOLE) DERIVATIVE, INK COMPRISING SAME, AND ORGANIC ELECTRONIC DEVICE COMPRISING SAME | FUTURE INK CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160276598-A1 | BENZOBIS (THIADIAZOLE) DERIVATIVE, INK COMPRISING SAME, AND ORGANIC ELECTRONIC DEVICE COMPRISING SAME | FUTURE INK CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-3048107-A1 | BENZOBIS (THIADIAZOLE) DERIVATIVE, INK CONTAINING SAME, AND ORGANIC ELECTRONIC DEVICE USING SAME | UBE Industries, Ltd. (JP) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015041026-A1 | BENZOBIS (THIADIAZOLE) DERIVATIVE, INK CONTAINING SAME, AND ORGANIC ELECTRONIC DEVICE USING SAME | 宇部興産株式会社 | 2015-03-26 | — | — | WO | disclosed |
| US-8952016-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8022076-B2 | Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents | XENTION LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160276598-A1 | BENZOBIS (THIADIAZOLE) DERIVATIVE, INK COMPRISING SAME, AND ORGANIC ELECTRONIC DEVICE COMPRISING SAME | BRD3, TH, BRS3 | ERN1 626/4885NOTUM 1677/4885KCNH2 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.